Differential effects of FTY720 on the B cell compartment in a mouse model of multiple sclerosis

[1]  K. Anja.  European Committee for Treatment and Research in Multiple Sclerosis , 2019, Kinder- und Jugendmedizin.

[2]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[3]  A. Traboulsee,et al.  Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.

[4]  S. Zamvil,et al.  B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. , 2016, JCI insight.

[5]  H. Wiendl,et al.  Annals of Clinical and Translational Neurology , 2014, Annals of clinical and translational neurology.

[6]  N. Hellings,et al.  Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study , 2014, PloS one.

[7]  P. Lehmann,et al.  Identification of a B cell-dependent subpopulation of multiple sclerosis by measurements of brain-reactive B cells in the blood. , 2014, Clinical immunology.

[8]  T. Yamamura,et al.  Differential effects of fingolimod on B-cell populations in multiple sclerosis , 2014, Multiple sclerosis.

[9]  R. Gold,et al.  Journal of Central Nervous System Disease , 2022 .

[10]  M. Snyder,et al.  Defective sphingosine-1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation , 2013, Nature Immunology.

[11]  Yasuyuki Kihara,et al.  Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy , 2013, Journal of the Neurological Sciences.

[12]  E. Meinl,et al.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis , 2013, Nature Reviews Neurology.

[13]  P. Lehmann,et al.  Tertiary lymphoid organ development coincides with determinant spreading of the myelin-specific T cell response , 2012, Acta Neuropathologica.

[14]  A. Damasceno,et al.  Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients , 2012, Multiple sclerosis.

[15]  Jenna M. Sullivan,et al.  Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. , 2011, Immunity.

[16]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[17]  Jeffrey A. Cohen,et al.  Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis , 2011, Annals of neurology.

[18]  S. Cepok,et al.  Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS , 2011, Neurology.

[19]  V. Brinkmann.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system , 2009, British journal of pharmacology.

[20]  Michael D. Davis,et al.  B lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a mechanism independent of sphingosine-1-phosphate-mediated chemotaxis. , 2009, Immunity.

[21]  D. Bourdette,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.

[22]  L. Kappos,et al.  FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis , 2008, Neurology.

[23]  M. Salvetti,et al.  B cells and multiple sclerosis , 2008, The Lancet Neurology.

[24]  Matthias Mueller,et al.  Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure. , 2008, International immunology.

[25]  D. Gray,et al.  Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells , 2007, Proceedings of the National Academy of Sciences.

[26]  U. V. von Andrian,et al.  Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. , 2006, The New England journal of medicine.

[27]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[28]  P. Lehmann,et al.  MBP-PLP fusion protein-induced EAE in C57BL/6 mice , 2006, Journal of Neuroimmunology.

[29]  B. Weinshenker,et al.  Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange , 2005, The Lancet.

[30]  J. Cyster,et al.  FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[32]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[33]  H. Amemiya,et al.  Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment , 2003, Journal of Pharmacology and Experimental Therapeutics.

[34]  M. Ikekita,et al.  T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl‐2 , 2002, British journal of pharmacology.

[35]  Emad S. Alnemri,et al.  CARD11 and CARD14 Are Novel Caspase Recruitment Domain (CARD)/Membrane-associated Guanylate Kinase (MAGUK) Family Members that Interact with BCL10 and Activate NF-κB* , 2001, The Journal of Biological Chemistry.

[36]  V. Brinkmann,et al.  FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. , 2001, Transplantation proceedings.

[37]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[38]  R. Zinkernagel,et al.  FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory1 , 2000, The Journal of Immunology.

[39]  S. Levy,et al.  CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. , 1998, Annual review of immunology.

[40]  J. Barrett,et al.  Induction of apoptosis by c-Fos protein , 1996, Molecular and cellular biology.

[41]  A. Hata,et al.  Tyrosine kinases Lyn and Syk regulate B cell receptor‐coupled Ca2+ mobilization through distinct pathways. , 1994, The EMBO journal.

[42]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[43]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.

[44]  J. Mussini,et al.  [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.